Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A

C X Gong1, I Grundke-Iqbal, K Iqbal

  • 1New York State Institute for Basic Research in Developmental Disabilities, Staten Island 10314.

Neuroscience
|August 1, 1994
PubMed

Insights

Protein phosphatase-2A dephosphorylates abnormal tau protein at specific sites, suggesting its role in Alzheimer's disease pathogenesis alongside protein phosphatase-2B. A deficiency in these phosphatases may contribute to tau hyperphosphorylation.

Area of Science:

  • Neuroscience
  • Biochemistry

Background:

  • Abnormal hyperphosphorylation of tau protein is a hallmark of Alzheimer's disease (AD).
  • Hyperphosphorylated tau forms paired helical filaments and other aggregates in AD brains.
  • A significant pool of non-paired helical filament abnormally phosphorylated tau also exists in AD.

Purpose of the Study:

  • To investigate the site-specific dephosphorylation of abnormally phosphorylated tau by protein phosphatase-2A (PP2A).
  • To compare the activity of PP2A with protein phosphatase-2B (PP2B) in dephosphorylating tau.
  • To explore the potential involvement of PP2A and PP2B deficiencies in AD-related tau pathology.

Main Methods:

  • Site-specific dephosphorylation of AD-associated hyperphosphorylated tau by PP2A and PP2B.
  • Detection of dephosphorylation using phosphorylation-dependent antibodies targeting specific tau sites (Ser-46, Ser-199, Ser-202, Ser-396, Ser-404, Ser-235).
  • Analysis of changes in tau mobility on SDS-PAGE post-dephosphorylation and the effect of Mn2+ stimulation.

Main Results:

  • PP2A effectively dephosphorylated tau at Ser-46, Ser-199, Ser-202, Ser-396, and Ser-404, but not Ser-235.
  • Both PP2A1 and PP2A2 isoforms dephosphorylated tau at similar rates.
  • Dephosphorylation by PP2A increased tau's relative mobility on SDS-PAGE and was stimulated by Mn2+.

Conclusions:

  • Tau dephosphorylation is catalyzed by PP2A, in addition to PP2B.
  • PP2A plays a significant role in regulating tau phosphorylation.
  • Deficiencies in PP2A or PP2B may contribute to the abnormal tau phosphorylation observed in Alzheimer's disease.

Related Concept Videos

Phosphorylation01:02

Phosphorylation

The addition or removal of phosphate groups from proteins is the most common chemical modification that regulates cellular processes. These modifications can affect the structure, activity, stability, and localization of proteins within cells as well as their interactions with other proteins.
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...